Summary of Study ST000976

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000666. The data can be accessed directly via it's Project DOI: 10.21228/M8KQ3J This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST000976
Study TitleGC6-74 matabolomic of TB (Part 3: Plasma_RPMI)
Study TypeMetabolomic analysis of TB vs heathy including time to TB.
Study SummaryWithin the GC6-74 cohorts, 4,462 HIV-negative healthy household contacts of 1,098 index TB cases were recruited from 2006 to 2012 at four African sites included in this study i.e. SUN (Stellenbosch University, South Africa), MRC (Medical Research Council Unit, The Gambia), AHRI (Armauer Hansen Research Institute, Ethiopia) and MAK (Makerere University, Uganda). The study had an exclusion period of 3 months, such that participants, who were diagnosed with active TB within 3 months of enrolment, were excluded from analysis to prevent inclusion of participants who had incipient or asymptomatic clinical TB disease at enrolment. Additional exclusion criteria were positive HIV rapid test, current or previous anti-retroviral treatment, history of TB, pregnancy, participation in drug and/or vaccine clinical trials and chronic disease diagnosis or immunosuppressive therapy within the past 6 months, and living in the study area for less than 3 months. A total of 97 individuals who developed active TB within the two year follow-up period were included in this study and matched at a ratio of 1:4 with participants who remained healthy during the 2-year follow-up period (controls); matching, by site, age class, sex, and wherever possible year of recruitment. Initial samples collected upon enrolment were termed baseline (BL) samples. Further samples were taken 6 and 18 months post-exposure, provided that the participant had remained TB free at the time of sample collection. Metabolic profiling was carried out for each study site, using either serum or plasma samples. For a small number of samples, an insufficient amount of plasma was available, so the sample was diluted using RPMI buffer.
Max Planck Institute for Infection Biology
Last NameKaufmann
First NameStefan
AddressCharit├ęplatz 1,10117 Berlin, Berlin, Deutschland
Phone+49 30 28460-500
Submit Date2018-05-15
Analysis Type DetailLC-MS
Release Date2018-11-05
Release Version1
Stefan Kaufmann Stefan Kaufmann application/zip

Select appropriate tab below to view additional metadata details:

Combined analysis:

Analysis ID AN001597
Analysis type MS
Chromatography type Unspecified
Chromatography system None
Column none
MS instrument type Orbitrap
MS instrument name Thermo Q Exactive Orbitrap
Units scaled units


MS ID:MS001475
Analysis ID:AN001597
Instrument Name:Thermo Q Exactive Orbitrap
Instrument Type:Orbitrap
MS Comments:The formulas were provided by Metabolon, Inc. who did the compound identification. The asterisks indicate the level of certainty about compound identification from mass spectroscopy: * indicates that a compound that has not been confirmed based on a standard, but we are confident in its identity; ** implies that a compound for which a standard is not available, but we are reasonably confident in its identity or the information provided. Basically, there is no standard available to confirm its identity.